– Largest hypertension trial of an aldosterone synthase inhibitor to date demonstrated the efficacy of lorundrostat in over 1,000 participants with uncontrolled or resistant hypertension in a real-world setting – – Lorundrostat 50 mg dosed once daily demonstrated clinically meaningful and sustained reductions in systolic blood pressure, with a 16.9 mmHg reduction at Week 6 (-9.1 mmHg placebo adjusted) and a 19.0 mmHg reduction at Week 12 (-11.7mm placebo adjusted) – – Lorundrostat demonstrated a favorable s ...

Oslo, 24 May 2025: Zelluna ASA (the "Company") refers to the resolution by the Company's Annual General Meeting held on 29 April 2025 to grant the Company's Board of Directors an authorisation to issue new shares, each with a subscription price of NOK 26, to settle an amount of EUR 500,000 of an already triggered option exercise fee towards Inven2. The Company's Board of Directors has today resolved to issue 227,096 new shares in the Company to Inven2 against set-off of such amount of EUR 500,000. After the ...

Core Viewpoint - NextGen Digital Platforms Inc. has successfully completed the third and final tranche of its non-brokered private placement, raising a total of approximately $2.83 million through the issuance of special warrants and common shares [1][3]. Group 1: Offering Details - The third tranche involved the issuance of 2,468,032 special warrants at a price of $0.30 each, generating gross proceeds of $740,409.74 [1]. - In total, the company issued 8,979,498 special warrants and 440,000 common shares during the entire offering, resulting in total gross proceeds of $2,825,849.84 [3]. - The company paid finder's fees totaling $54,712.01 in cash and issued 162,533 Finder's Warrants as part of the offering [3]. Group 2: Special Warrants Conversion - Each special warrant will automatically convert into one common share without additional consideration, either three business days after filing a prospectus supplement or four months and one day after the offering's closing [4]. - The company aims to file the prospectus supplement within 60 days of the offering's closing, although there is no guarantee this will occur before the statutory hold period expires [5]. Group 3: Use of Proceeds - The net proceeds from the offering will be utilized for corporate development, marketing, and general working capital [6]. Group 4: Marketing Agreement - The company has entered into a marketing agreement with Alpha Collective Inc. for digital marketing services, with a cash fee of $45,000 for a three-month term starting May 21, 2025 [7].

Core Viewpoint - BioSig Technologies, Inc. has signed a definitive share exchange agreement with Streamex Exchange Corporation, marking a significant milestone in the business combination aimed at enhancing the tokenization of real-world assets, particularly in the commodities sector [1][2]. Company Overview - BioSig Technologies is a medical technology company focused on innovative solutions, while Streamex specializes in the tokenization of real-world assets, particularly commodities [1][7]. - The combined entity will be led by Henry McPhie, Co-Founder and CEO of Streamex, with Anthony Amato transitioning to a board role [5]. Transaction Highlights - The share exchange will result in Streamex becoming a wholly owned subsidiary of BioSig, with existing Streamex shareholders entitled to receive 75% of the fully diluted BioSig common stock post-transaction [5][12]. - The transaction is expected to unlock new value in the US$142.85 trillion global commodity market by bringing commodities on-chain through secure tokenization solutions [5][13]. Strategic Additions - Notable strategic advisors have joined the combined company, including Frank Giustra, Mathew August, and Mitchell Williams, bringing extensive experience in commodities and capital markets [6]. Market Positioning - Streamex aims to revolutionize commodity finance by bridging traditional finance with the digital economy, enhancing liquidity, accessibility, and efficiency through innovative financial technologies and blockchain [8].

Core Points - Advent Technologies Holdings, Inc. has received a notification from Nasdaq regarding non-compliance with listing requirements due to late filings of its Quarterly Report on Form 10-Q and Annual Report on Form 10-K [1][2] - The company has until June 16, 2025, to submit a compliance plan to Nasdaq, which, if accepted, may allow an extension until October 13, 2025, to regain compliance [2][3] - Advent Technologies specializes in developing and manufacturing fuel cell systems and holds over 150 patents related to fuel cell technology [4] Company Overview - Advent Technologies Holdings, Inc. is based in Livermore, California, with additional offices in Athens and Patras, Greece [4] - The company focuses on renewable energy, particularly in fuel cell technology, suitable for various sectors including automotive, aviation, defense, oil and gas, marine, and power generation [4] - The company possesses intellectual property for next-generation HT-PEM fuel cells that operate under high temperatures and extreme conditions [4]

Core Viewpoint - IMUNON, Inc. has announced a private placement of common stock and short-term warrants, aiming to raise approximately $3.25 million, with potential additional proceeds of up to $6.5 million from the exercise of warrants [1][3]. Group 1: Financial Details - The company will issue 7,222,223 shares of common stock at a price of $0.45 per share, along with short-term warrants to purchase up to 14,444,446 additional shares [1][3]. - The offering is expected to close around May 27, 2025, pending customary closing conditions [1]. - The net proceeds from the offering will be used for working capital and general corporate purposes [3]. Group 2: Regulatory and Offering Structure - The securities are offered in a private placement under Section 4(a)(2) of the Securities Act of 1933 and Regulation D, and have not been registered under the Act [4]. - The offering is limited to accredited investors, and the company has agreed to file registration statements with the SEC for resale of the shares [4]. Group 3: Company Overview - IMUNON is a clinical-stage biotechnology company focused on DNA-mediated immunotherapy, with a lead program targeting advanced ovarian cancer [6][7]. - The company is developing innovative treatments that utilize the body's natural mechanisms to generate effective responses against various diseases [6]. - IMUNON's first modality, TheraPlas, is aimed at gene-based delivery of therapeutic proteins, while the second modality, PlaCCine, focuses on gene delivery of viral antigens [6].

Core Viewpoint - Teck Resources Limited has received an unsolicited mini-tender offer from TRC Capital Corporation to purchase up to 2.0 million Class B subordinate voting shares at a price of $47.80, which is a 4.46% discount to the closing price on May 20, 2025 [1][2]. Group 1: Mini-Tender Offer Details - The mini-tender offer represents approximately 0.41% of Teck's outstanding Class B subordinate voting shares as of May 23, 2025 [1]. - Teck advises shareholders not to tender their shares due to the below-market price of the offer and various conditions attached to TRC's offer [3][4]. - TRC's offer includes subjective conditions and is designed to avoid many investor protections applicable to larger tender offers [4]. Group 2: Shareholder Guidance - Teck does not endorse TRC's unsolicited offer and emphasizes that shareholders should exercise caution and consult financial advisors before making decisions [4]. - The Canadian Securities Administrators have raised concerns about mini-tender offers, warning that investors might misunderstand the terms and pricing relative to market conditions [5]. - Shareholders who have tendered their shares can withdraw them before June 18, 2025, by following the procedures outlined in TRC's offer documents [7]. Group 3: Company Overview - Teck is a leading Canadian resource company focused on providing essential metals for economic development and energy transition, with operations in North and South America [11]. - The company is committed to responsible growth and stakeholder trust, with a strong portfolio in copper and zinc operations [11].

Core Viewpoint - Mustang Energy Corp. has initiated its 2025 field exploration program at the 914W Project, located in a mineral-rich area south of the Athabasca Basin, aiming to advance its exploration strategy through systematic activities [1][2][3]. Group 1: Project Overview - The 914W Project is approximately 48 km southwest of Cameco's Key Lake Operation, with favorable logistics via Highway 914 [3]. - The project area has shown promising geological features, including local graphite-bearing assemblages and historical mineralization results, such as up to 1,288 ppm U in drill hole ML-11 and up to 0.64% U3O8 in surface prospecting at Don Lake Zone E [4][3]. Group 2: Exploration Activities - The field program will consist of surface prospecting activities, including detailed rock and soil sampling over nine days, aimed at identifying mineralization zones [2]. - Results from this initial phase are expected to guide future exploration efforts, including potential geophysical surveys or drilling [2]. Group 3: Company Strategy - Mustang Energy Corp. is focused on acquiring and developing high-potential uranium and critical mineral assets, holding a total of 92,211 hectares in the Athabasca Basin [8]. - The company sees significant potential for advancing uranium and rare earth element exploration on the 914W Project, which remains largely underexplored despite previous surveys [6].

Core Viewpoint - Imperial Metals Corporation has announced its intention to initiate a Normal Course Issuer Bid to repurchase up to 814,089 common shares, representing 0.5% of its total outstanding shares, as part of its strategy to manage capital and fulfill obligations under its share plans [1][2]. Group 1: Bid Details - The company plans to commence the share repurchase on May 28, 2025, and it will conclude no later than May 27, 2026 [2]. - Daily purchases will be limited to 12,792 common shares or 25% of the average daily trading volume of 51,168 common shares on the TSX [2]. - The shares repurchased will be allocated to satisfy obligations under the Non-Management Directors' Plan and Amended and Restated Share Purchase Plan [2]. Group 2: Historical Context - In the past 12 months, the company repurchased 217,504 common shares at a volume-weighted average price of $2.37 [2]. - The maximum number of shares approved for repurchase in the previous bid was 809,357 [2]. Group 3: Company Overview - Imperial Metals is based in Vancouver and is involved in exploration, mine development, and operations, with ownership of the Mount Polley mine, Huckleberry mine, and a 30% stake in the Red Chris mine [3]. - The company also holds a portfolio of 23 greenfield exploration properties in British Columbia [3].

Core Insights - Clean Energy Technologies, Inc. (CETY) has signed a Non-Binding Offer (NBO) with a European solar and wind development company, aiming to expand its operations into Europe and tap into the renewable energy market [1][3]. Financial Summary - CETY has secured an initial equity investment of $4,400,000, which will contribute to the estimated total deal size of approximately $85,000,000, contingent on scheduled milestones [2]. Market Expansion - The transaction is expected to provide CETY with a foothold in the lucrative European market for solar and wind power generation, supported by stable government policies that favor long-term growth in renewable energy [3]. Company Overview - CETY is headquartered in Irvine, California, and focuses on zero-emission energy solutions, including waste heat recovery and waste-to-energy technologies, catering to small and mid-sized projects across North America, Europe, and Asia [4]. Stock Information - CETY's common stock is traded on the Nasdaq Capital Market under the symbol "CETY" [5].